Nurses will play a more prominent role in health care. An Institute of Medicine study, The Future of Nursing: Focus on Scope of Practice, states that “[N]urses have a considerable opportunity to act as full partners with other health professionals and to lead in the improvement and redesign of the health care system and its practice environment.” The average base salary for chief nursing officers rose in 2011 a little more slowly than in 2010, according to Executive Compensation 2011/2012, published by Compdata Surveys.

The chief nursing officer is responsible “for planning, organizing, and controlling the department of nursing and patient services,” says Compdata. In addition, the CNO, who should have a master’s degree at least, has “responsibility, authority, and accountability for nursing practice, nursing education, and nursing research activities.” The CNO interacts with other hospital department heads.

In other words, the CNO is a player, but that’s not surprising. We reported in March on a Gallup poll of health care officials, conducted by the Robert Wood Johnson Foundation, that examined how nurses might drive change. “Opinion leaders feel [that] society, and nurses themselves, should have higher expectations for what nurses can achieve, and that nurses should be held accountable for not only providing quality direct patient care, but also health care leadership.”

2011 CNO salaries by revenue for the organization …

… and by size of organization

Chief nursing officers for the most part were not offered huge incentives

Source: Executive Compensation 2011/2012, Compdata Surveys

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.